18 reports

The company produces and markets high-quality products and biologics in the areas of gastrointestinal disease, neurology, psychiatry, immunology, pain control, infectious disease, and oncology.

  • Cancer Hormonal Therapy
  • China
  • AstraZeneca China Inc.
  • Bayer Schering Pharmaceutical Co., Ltd
  • Beijing Novartis Pharma Ltd
  • 2.8.1 TREATMENT ALGORITHM

The combination was well tolerated, with common adverse effects including peripheral neuropathy, gastrointestinal symptoms and fatigue.

  • Cancer Hormonal Therapy
  • World
  • Market Size
  • Celgene Corporation
  • Novartis AG
  • 2.8.1 TREATMENT ALGORITHM

The combination was well tolerated, with common adverse effects including peripheral neuropathy, gastrointestinal symptoms and fatigue.

  • Cancer Hormonal Therapy
  • World
  • Market Size
  • Celgene Corporation
  • Novartis AG

THE MOST COMMON GRADE ##-## ADVERSE EVENTS INCLUDED NEUTROPENIA (##%), HYPOKALEMIA (##%), HYPOPHOSPHATEMIA (##%), RASH (##%), TUMOR FLARE (##%) AND GASTROINTESTINAL COMPLAINTS (##%).

  • Cancer Hormonal Therapy
  • Therapy
  • Europe
  • United States
  • Celgene Corporation

OPROZOMIB IS ASSOCIATED WITH GASTROINTESTINAL TOXICITIES, WITH THE MOST COMMON GRADE ## AES BEING DIARRHEA, NAUSEA, AND VOMITING.

  • Cancer Hormonal Therapy
  • Forecast
  • Celgene Corporation
  • Janssen Biotech, Inc.
  • Novartis AG

Oprozomib is associated with gastrointestinal toxicities, with the most common Grade ## AEs being diarrhea, nausea, and vomiting.

  • Cancer Hormonal Therapy
  • Janssen Biotech, Inc.
  • Novartis AG
  • PharmaMar SA
  • Takeda Pharmaceutical Company Limited

Oprozomib is associated with gastrointestinal toxicities, with the most common Grade ## AEs being diarrhea, nausea, and vomiting.

  • Cancer Hormonal Therapy
  • National Comprehensive Cancer Network, Inc.
  • Novartis AG
  • PharmaMar SA
  • Takeda Pharmaceutical Company Limited

Oprozomib is associated with gastrointestinal toxicities, with the most common Grade ## AEs being diarrhea, nausea, and vomiting.

  • Cancer Hormonal Therapy
  • National Comprehensive Cancer Network, Inc.
  • Novartis AG
  • PharmaMar SA
  • Takeda Pharmaceutical Company Limited

Oprozomib is associated with gastrointestinal toxicities, with the most common Grade ## AEs being diarrhea, nausea, and vomiting.

  • Cancer Hormonal Therapy
  • Japan
  • Novartis AG
  • PharmaMar SA
  • Takeda Pharmaceutical Company Limited
  • Trial Results

Based on the interim results presented, GlobalData inferred that the most commonly affected organ class was the gastrointestinal system (all grade, ##% vs grade ##/ ##, ##. ##%), of which diarrhea was most common (all grade, ##% vs grade ##/ ##, ##%).

  • Cancer Hormonal Therapy
  • United States
  • World
  • Celgene Corporation
  • Novartis AG

We anticipate that this regimen will continue to show reduced rates of cytopenias, neuropathy and gastrointestinal side effects based on the continuing STOMP results.

  • Cancer Hormonal Therapy
  • Lymphoma
  • United States
  • World
  • Karyopharm Therapeutics Inc.

Common toxicities were hematological and gastrointestinal.

  • Cancer Hormonal Therapy
  • Lung Cancer
  • United States
  • Product Initiative
  • Acetylon Pharmaceuticals, Inc.

Primary Systemic Amyloidosis Global Clinical Trials Review, H##, 2016 Reference Code: GDHC##CTIDB Publication Date: JUN 2016 LIST OF TABLES Primary Systemic Amyloidosis Global Clinical Trials Review, H##, 2016 outlines clinical trials in Primary Systemic Amyloidosis.

  • Cancer Hormonal Therapy
  • Endocrine Disease
  • Leukemia
  • Pathology
  • Celgene Corporation

It provides multivitamins and antianemic agents, contact lens care and ophthalmic agents, antifungal agents, cardiovascular agents, and gastrointestinal agents.

  • Cancer Hormonal Therapy
  • Pathology
  • Therapy
  • United States
  • Product Initiative

A single infusion of CAEL-## or one weekly infusion for four weeks have demonstrated early and sustained organ response in cardiac, renal, gastrointestinal, skin and soft tissue.

  • Cancer Hormonal Therapy
  • Clinical Trial
  • Therapy
  • World
  • Product Initiative
  • Clinical Trial Profile Snapshots

Gastrointestinal Tract GDCT## NCT##, A## Oncology Hormone Sensitive Breast Cancer Completed Phase I Interventional palbociclib Pfizer Inc. ## Jun 2013 ## Aug 2013 Official Title Clinical Trial profile. ## Trial Title Trial Identifier Secondary ID(s) Therapy Area Indication(s

  • Breast Cancer
  • Cancer Hormonal Therapy
  • Hormone
  • World
  • Pfizer Inc.
  • Clinical Trial Profile Snapshots

Gastrointestinal Tumor, Gynecological Cancer, Head And Neck Cancer, Leukemias, Lymphoma, Melanoma, Myelodysplastic Syndrome, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Solid Tumor, Waldenstrom Macroglobulinemia Ongoing, recruiting Phase I Interventional ##IGF-MTX University of

  • Cancer Hormonal Therapy
  • Lymphoma
  • United States
  • World
  • Celgene Corporation

As predicted from its targeted mechanism, ARRY-## has exhibited no neuropathy, alopecia or serious gastrointestinal effects at its recommended dose.

  • Cancer Hormonal Therapy
  • Hospital
  • Therapy
  • United States
  • Product Initiative